Latest Breaking News On - Eurazeo group - Page 1 : comparemela.com

EURAZEO : CONTINUES TO GROW ITS ASSET MANAGEMENT ACTIVITY AND INCREASES REALIZATIONS IN Q1 2024

EURAZEO : CONTINUES TO GROW ITS ASSET MANAGEMENT ACTIVITY AND INCREASES REALIZATIONS IN Q1 2024
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

William kadouch chassaingChristophe baviEurazeo groupEurazeo planetary boundaries fundPaying assets under managementUnder managementEurazeo assets under managementLimited partnersWealth managementEurazeo private value europeAmolyt pharmaPeters surgicalExecutive boardLong term incentive plansAssets under managementLitman gregory wealth management

Eurazeo : UK Tax Strategy-2022 -December 18, 2023 at 08:45 am EST

Eurazeo Group Tax Strategy for Financial Year 2022 Scope The Eurazeo group is publishing this tax strategy statement on behalf of its U.K..

Audit committee of eurazeoEurazeo groupEurazeo group tax strategy for financial yearEurazeo group tax strategyFinancial yearFinance actExecutive boardTax structuring directorAudit committeeSenior accounting officer

EURAZEO : TAX STRATEGY FOR FINANCIAL YEAR 2023 -December 18, 2023 at 06:13 am EST

Eurazeo Group Tax Strategy for Financial Year 2023 Scope The Eurazeo group is publishing this tax strategy statement.

Eurazeo group tax strategy for financial yearEurazeo groupAudit committee of eurazeoEurazeo group tax strategyFinancial yearFinance actExecutive boardAudit committeeSenior accounting officer

Eurazeo : 2023 3rd Quarter revenue -November 10, 2023 at 05:34 pm EST

Dynamic asset management growth over the first 9-months of 2023 Assets Under Management : +11% pro forma in one year to €33.5bn .

United kingdom generalUnited kingdomWilliam kadouch chassaingChristophe baviEurazeo groupEurazeo transition infrastructure fundUnder managementPaying assets under managementEurazeo smart cityFee related earningsCapital markets dayEurazeo assets under managementLimited partnersWealth managersPrivate debtTransition infrastructure fund

Shorla Oncology Secures $35M Series B Funding Round to Advance its Oncology Product Portfolio

CAMBRIDGE, Mass., October 04, 2023 Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, today announced that it has raised $35 million in Series B funding, led by Kurma Partners’ Growth Opportunities Fund, with participation from existing investors Seroba Life Sciences and Irish, U.S. and Canadian based family offices and Enterprise Ireland. The funding will enable Shorla to accelerate the growth of its oncology portfolio by advancing its pipeline, bringing therapies to

United kingdomKurma biofundSharon cunninghamDaniel pareraOrlaith ryanUs department of healthSeroba life sciencesKurma partner growth opportunities fundGrowth opportunities fundHuman servicesEurazeo groupShorla oncologyNelarabine injectionSpecialty pharmaEuropean healthcareLife science